Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

[Image: see text] The development of small-molecule MDM2 inhibitors to restore dysfunctional p53 activities represents a novel approach for cancer treatment. In a previous communication, the efforts leading to the identification of a non-imidazoline MDM2 inhibitor, RG7388, was disclosed and revealed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhang, Zhuming, Chu, Xin-Jie, Liu, Jin-Jun, Ding, Qingjie, Zhang, Jing, Bartkovitz, David, Jiang, Nan, Karnachi, Prabha, So, Sung-Sau, Tovar, Christian, Filipovic, Zoran M., Higgins, Brian, Glenn, Kelli, Packman, Kathryn, Vassilev, Lyubomir, Graves, Bradford
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2013
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027646/
https://ncbi.nlm.nih.gov/pubmed/24900784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml400359z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados